Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-EDV-Dox/GC for recurrent glioblastoma
ACTRN12625000779471Phase 2Recruiting
- Sponsor
- EnGeneIC
- Start
- Apr 2026
- Modality
- Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of E-EDV-Dox and EDV-GC in glioblastoma (GBM), sponsored by EnGeneIC. Primary endpoint: Incidence and severity of adverse events. Started Apr 2026; status: recruiting.
02
Drugs
E-EDV-DoxEDV-GC
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12625000779471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000779471.